natgillin/translations-raw huggingface dataset:
The total body clearance of sildenafil is 41 l/h with a resultant terminal phase half-life of 3-5 h. After either oral or intravenous administration, sildenafil is excreted as metabolites predominantly in the faeces (approximately 80 % of administered oral dose) and to a lesser extent in the urine (approximately 13 % of administered oral dose). 
Sildenafil se po peroralni in intravenski uporabi izloči v obliki presnovkov, pretežno v blatu (približno 80 % peroralnega odmerka) in v manjši meri v urinu (približno 13 % peroralnega odmerka).
- The other ingredients are: Tablet core: microcrystalline cellulose, calcium hydrogen phosphate (anhydrous), croscarmellose sodium, magnesium stearate. 
Jedro tablete: mikrokristalna celuloza, brezvodni kalcijev hidrogenfosfat, premreženi natrijev karmelozat, magnezijev stearat.
Discard any remaining suspension 30 days after constitution. 
Preostalo suspenzijo zavrzite v 30 dneh po rekonstituciji.
Side effects reported very commonly (may affect more than 1 in 10 people) were headache, vomiting, infection of the throat, fever, diarrhoea, flu and nosebleed. 
Zelo pogosto opisani neželeni učinki (pojavijo se lahko pri več kot 1 od 10 bolnikov) so glavobol, bruhanje, okužba žrela, vročina, driska, gripa in krvavitev iz nosu.
Adverse reactions which occurred in > 1 % of Revatio-treated patients and were more frequent (> 1 % difference) on Revatio in the pivotal study or in the Revatio combined data set of both the placebo-controlled studies in pulmonary arterial hypertension, at doses of 20, 40 or 80 mg TID are listed in the table below by class and frequency grouping (very common ( 1/10), common ( 1/100 to < 1/10), uncommon ( 1/1000 to < 1/100) and not known (cannot be estimated from the available data). 
Neželeni učinki, ki so se pojavili pri > 1 % bolnikov, zdravljenih z zdravilom Revatio, ter so bili v ključni študiji oziroma v združenih podatkih iz obeh s placebom nadzorovanih študij pljučne arterijske hipertenzije ob odmerkih 20, 40 ali 80 mg trikrat na dan pogostejši pri jemanju zdravila (razlika > 1 %), so prikazani v spodnji preglednici po organskem sistemu in pogostnosti: zelo pogosti ( 1/10), pogosti ( 1/100 do <1/10), občasni ( 1/1.000 do ≤ 1/100) in neznana (ni mogoče oceniti iz podatkov, ki so na voljo).
Adverse reactions which occurred in > 1 % of Revatio-treated patients and were more frequent (> 1 % difference) on Revatio in the pivotal study or in the Revatio combined data set of both the placebo-controlled studies in pulmonary arterial hypertension, at oral doses of 20, 40 or 80 mg TID are listed in the table below by class and frequency grouping (very common ( 1/10), common ( 1/100 to < 1/10), uncommon ( 1/1000 to ≤ 1/100) and not known (cannot be estimated from the available data). 
Neželeni učinki, ki so se pojavili pri > 1 % bolnikov, zdravljenih z zdravilom Revatio, ter so bili v ključni študiji oziroma v združenih podatkih iz obeh s placebom nadzorovanih študij pljučne arterijske hipertenzije ob peroralnih odmerkih 20, 40 ali 80 mg trikrat na dan pogostejši pri jemanju zdravila (razlika > 1 %), so prikazani v spodnji preglednici po organskem sistemu in pogostnosti: zelo pogosti ( 1/10), pogosti ( 1/100 do < 1/10), občasni ( 1/1.000 do ≤ 1/100) in neznana (ni mogoče oceniti iz podatkov, ki so na voljo).
Co-administration of oral contraceptives (ethinyloestradiol 30 g and levonorgestrel 150 g) did not affect the oral pharmacokinetics of sildenafil. 
Sočasna uporaba peroralnih kontraceptivov (30 g etinilestradiola in 150 g levonorgestrela) ni vplivala na peroralno farmakokinetiko sildenafila.
A 10 mg dose of Revatio solution for injection is predicted to provide exposure of sildenafil and its N-desmethyl metabolite and pharmacological effects comparable to those of a 20 mg oral dose. 
Revatio raztopina za injiciranje v odmerku 10 mg predvidoma doseže takšno izpostavljenost sildenafilu in njegovemu N-dezmetilnemu presnovku ter takšne farmakološke učinke, ki so primerljivi s peroralnim odmerkom 20 mg.
Sildenafil had no clinically significant impact on the plasma levels of oral contraceptives (ethinyloestradiol 30 g and levonorgestrel 150 g). 
Sildenafil nima klinično pomembnega vpliva na koncentracijo peroralnih kontraceptivov (30 g etinilestradiola in 150 g levonorgestrela) v plazmi.
Revatio is for oral use only. 
Zdravilo Revatio je le za peroralno uporabo.
The population pharmacokinetic analysis in pulmonary arterial hypertension patients receiving oral sildenafil suggested that co-administration of beta-blockers in combination with CYP3A4 substrates might result in an additional increase in sildenafil exposure compared with administration of CYP3A4 substrates alone. 
Populacijska farmakokinetična analiza pri bolnikih s pljučno arterijsko hipertenzijo, ki so prejemali peroralni sildenafil, je pokazala, da lahko sočasna uporaba antagonistov beta in substratov CYP3A4 v primerjavi z uporabo substratov CYP3A4 samih, dodatno poveča izpostavljenosti sildenafilu.
You should be aware of how you react to the medicine before you drive or use machines. 
Zdravilo Revatio lahko povzroči omotico in vpliva na vid. Preden vozite ali upravljate stroje, morate vedeti, kako se odzivate na to zdravilo.
IMMEDIATE PACKAGING/BLISTER 
STIČNA OVOJNINA/PRETISNI OMOT
Children Revatio should not be given to children below 1 year of age. 
Otroci, mlajši od 1 leta, ne smejo jemati zdravila Revatio.
Adverse reactions reported in >10% of 229 subjects treated with sildenafil (combined dose group, including 9 patients that did not continue into the long-term study) were upper respiratory infection (31%), headache (26%), vomiting (22%), bronchitis (20%), pharyngitis (18%), pyrexia (17%), diarrhoea (15%), and influenza, epistaxis (12% each). 
glavobol (26 %), bruhanje (22 %), bronhitis (20 %), faringitis (18 %), pireksija (17 %), diareja (15 %), gripa in epistaksa (oba 12 %).
Oral sildenafil had no clinically significant impact on the plasma levels of oral contraceptives (ethinyloestradiol 30 g and levonorgestrel 150 g). 
Peroralni sildenafil nima klinično pomembnega vpliva na koncentracijo peroralnih kontraceptivov (30 g etinilestradiola in 150 g levonorgestrela) v plazmi.
BOTTLE 
STEKLENICA
A downward dose adjustment to 10 mg twice daily should be considered when sildenafil is co-administered to patients already receiving CYP3A4 inhibitors like erythromycin or saquinavir. 
O zmanjšanju odmerka na 10 mg dvakrat na dan je treba razmisliti pri bolnikih, ki dobijo sildenafil in že prejemajo zaviralce CYP3A4, npr. eritromicin ali sakvinavir.
In clinical trials the side effects reported commonly (may affect up to 1 in 10 people) were facial flushing, headache, low blood pressure and nausea. 
V kliničnih preskušanjih opisani pogosti neželeni učinki (pojavijo se lahko pri največ 1 od 10 bolnikov) so zardevanje, glavobol, nizek krvni tlak in občutek siljenja na bruhanje.
Higher than recommended doses should not be used in paediatric patients with PAH (see also sections 4.4 and 5.1). 
Zato se odmerkov, večjih od priporočenih, pri pediatričnih bolnikih s PAH ne sme uporabljati (glejte tudi poglavji 4.2 in 5.1).
The powder contains sorbitol. 
Intoleranca za fruktozo Prašek vsebuje sorbitol.
Note: A total volume of 90 ml (3 x 30 ml) of water irrespective of the dose you are taking should be used to reconstitute the contents of the bottle. 
Opomba: za rekonstitucijo vsebine steklenice je treba skupno uporabiti 90 ml (3 x 30 ml) vode, ne glede na odmerek, ki ga boste jemali.
Efficacy of oral sildenafil in adult patients with pulmonary arterial hypertension (PAH) A randomised, double-blind, placebo-controlled study was conducted in 278 patients with primary pulmonary hypertension, PAH associated with connective tissue disease, and PAH following surgical repair of congenital heart lesions. 
Učinkovitost peroralnega sildenafila pri odraslih bolnikih s pljučno arterijsko hipertenzijo (PAH) Pri 278 bolnikih s primarno pljučno arterijsko hipertenzijo (PAH), PAH povezano z boleznimi vezivnega tkiva in PAH po kirurški popravi prirojenih srčnih hib so izvedli randomizirano, dvojno slepo, s placebom nadzorovano študijo.
Add a total of 90 ml of water (3 x 30 ml) strictly following the package leaflet, ensuring the bottle is shaken vigorously after adding 60 ml and the remaining 30 ml. 
Steklenico dobro pretresite dvakrat: po dodatku 60 ml in nato po dodatku preostalih 30 ml vode.
Each 20 ml vial contains 12.5 ml (10 mg sildenafil, as citrate). 
Ena 20 ml viala vsebuje 12,5 ml (10 mg sildenafila v obliki sildenafilijevega citrata).
The sildenafil medium and high dose groups displayed mPAP changes from baseline compared to placebo, of -3.5 mmHg (95 % CI: -8.9, 1.9) and -7.3 mmHg (95 % CI: -12.4, -2.1), respectively; whilst the low dose group showed little difference from placebo (difference of 1.6 mmHg). 
V skupinah, ki sta prejemali sildenafil v srednjem in velikem odmerku, so ugotovili spremembe pri povprečnem arterijskem tlaku v pljučih glede na izhodiščno vrednost v primerjavi s placebom, in sicer v obsegu -3,5 mm Hg (95 % IZ: -8,9, 1,9) oziroma -7,3 mm Hg (95 % IZ: -12,4, -2,1); medtem ko so pri skupini, ki je prejemala majhen odmerek, ugotovili le majhno spremembo v primerjavi s placebom (razlika v obsegu 1,6 mm Hg).
In clinical trials with Revatio tablets side effects reported very commonly (may affect more than 1 in 10 people) were headache, facial flushing, indigestion, diarrhoea and pain in the arms or legs. 
V kliničnih preskušanjih s tabletami zdravila Revatio zelo pogosto opisani neželeni učinki (pojavijo se lahko pri več kot 1 od 10 bolnikov) so glavobol, zardevanje obraza, prebavne motnje, driska in bolečine v rokah ali nogah.
The percent reduction at 12 weeks for sildenafil 20 mg, 40 mg and 80 mg TID in PVR (11.2 %, 12.9 %, 23.3 %) was proportionally greater than the reduction in systemic vascular resistance (SVR) (7.2 %, 5.9 %, and 14.4 %). 
Odstotek znižanja pljučne žilne upornosti (11,2 % za 20 mg trikrat na dan, 12,9 % za 40 mg trikrat na dan in 23,3 % za 80 mg trikrat na dan) je bil po 12 tednih proporcionalno večji kot znižanje sistemske žilne upornosti (7,2 % za 20 mg trikrat na dan, 5,9 % za 40 mg trikrat na dan in 14,4 % za 80 mg trikrat na dan).
A downward dose adjustment to 10 mg once daily is recommended in case of co-administration with more potent CYP3A4 inhibitors like clarithromycin, telithromycin and nefazodone. 
Zmanjšanje odmerka na 10 mg enkrat na dan je priporočljivo v primeru sočasne uporabe z močnejšimi zaviralci CYP3A4, npr. s klaritromicinom, telitromicinom in nefazodonom.
No significant interactions were shown when oral sildenafil (50 mg) was co-administered with tolbutamide (250 mg) or warfarin (40 mg), both of which are metabolised by CYP2C9. 
Med sočasno uporabo peroralnega sildenafila (50 mg) in tolbutamida (250 mg) ali varfarina (40 mg), ki se presnavljata s CYP2C9, ni bilo pomembnih interakcij.
In addition, N-desmethyl metabolite AUC and Cmax values were significantly increased by 200 % and 79 % respectively in subjects with severe renal impairment compared to subjects with normal renal function. 
Poleg tega sta se pri preiskovancih s hudo okvaro ledvic v primerjavi s preiskovanci z normalnim delovanjem ledvic pomembno povečali AUC (za 200 %) in Cmax (za 79 %) N-dezmetilnega presnovka.
Effects of oral sildenafil on other medicinal products 
Učinki peroralnega sildenafila na druga zdravila
Pineapple juice concentrate Citric acid anhydrous Natural flavouring 
Aroma grozdja: maltodekstrin koncentrat grozdnega soka gumi akacije koncentrat ananasovega soka brezvodna citronska kislina naravna aroma
Replace the cap on the bottle. 
Na steklenico namestite zaporko.
When a single 100 mg dose of oral sildenafil was administered with erythromycin, a moderate CYP3A4 inhibitor, at steady state (500 mg twice daily for 5 days), there was a 182 % increase in sildenafil systemic exposure (AUC). 
Ob uporabi posamičnega 100 mg odmerka peroralnega sildenafila hkrati z eritromicinom, zmernim zaviralcem CYP3A4, je v stanju dinamičnega ravnovesja (500 mg dvakrat na dan 5 dni) prišlo do 182 % povečanja sistemske izpostavljenosti (AUC) sildenafilu.
The N-desmethyl metabolite is further metabolised, with a terminal half-life of approximately 4 h. In patients with pulmonary arterial hypertension, plasma concentrations of N-desmethyl metabolite are approximately 72 % those of sildenafil after 20 mg three times a day dosing (translating into a 36 % contribution to sildenafil's pharmacological effects). 
Pri bolnikih s pljučno arterijsko hipertenzijo je koncentracija N-dezmetilnega presnovka v plazmi približno 72 % koncentracije sildenafila po peroralni uporabi 20 mg trikrat na dan (kar pomeni 36 % prispevek k farmakološkim učinkom sildenafila).
For children and adolescents aged 1 year to 17 years old, the recommended dose is either 10 mg (1 ml of oral suspension) three times a day for children and adolescents weighing 20 kg or under, or 20 mg (2 ml of oral suspension) three times a day for children and adolescents weighing over 20 kg, taken with or without food. 
Pri otrocih in mladostnikih, starih od 1 leta do 17 let, priporočeni odmerek pri bolnikih s telesno maso, manjšo od 20 kg, znaša 10 mg (1 ml peroralne suspenzije) trikrat na dan, pri bolnikih s telesno maso, večjo od 20 kg, pa 20 mg (2 ml peroralne suspenzije) trikrat na dan, s hrano ali brez nje.
In the pivotal placebo-controlled study of Revatio in pulmonary arterial hypertension, a total of 207 patients were randomized to and treated with 20 mg, 40 mg, or 80 mg TID doses of Revatio and 70 patients were randomized to placebo. 
V ključni, s placebom nadzorovani študiji zdravila Revatio za zdravljenje pljučne arterijske hipertenzije, je skupno 207 bolnikov bilo randomiziranih in zdravljenih z zdravilom Revatio v odmerkih 20 mg, 40 mg ali 80 mg trikrat na dan, 70 bolnikov pa je bilo randomiziranih na placebo.
For children and adolescents aged 1 year to 17 years old, the recommended dose is either 10 mg three times a day for children and adolescents ≤ 20 kg or 20 mg three times a day for children and adolescents > 20 kg, taken with or without food. 
Pri otrocih in mladostnikih, starih od 1 leta do 17 let, priporočeni odmerek pri bolnikih s telesno maso  20 kg znaša 10 mg trikrat na dan, pri bolnikih s telesno maso > 20 kg pa 20 mg trikrat na dan, s hrano ali brez nje.
When a single 100 mg dose of sildenafil was administered with erythromycin, a moderate CYP3A4 inhibitor, at steady state (500 mg twice daily for 5 days), there was a 182 % increase in sildenafil systemic exposure (AUC). 
Ob uporabi posamičnega 100 mg odmerka sildenafila hkrati z eritromicinom, zmernim zaviralcem CYP3A4, je v stanju dinamičnega ravnovesja (500 mg dvakrat na dan 5 dni) prišlo do 182 % povečanja sistemske izpostavljenosti (AUC) sildenafilu.
Efficacy in adult patients with pulmonary arterial hypertension (PAH) A randomised, double-blind, placebo-controlled study was conducted in 278 patients with primary pulmonary hypertension, PAH associated with connective tissue disease, and PAH following surgical repair of congenital heart lesions. 
Učinkovitost pri odraslih bolnikih s pljučno arterijsko hipertenzijo (PAH) Pri 278 bolnikih s primarno pljučno arterijsko hipertenzijo (PAH), PAH povezano z boleznimi vezivnega tkiva in PAH po kirurški popravi prirojenih srčnih hib so izvedli randomizirano, dvojno slepo, s placebom nadzorovano študijo.
Once reconstituted one bottle contains 1.12 g of sildenafil (as citrate) with a final volume of 112 ml. 
Po rekonstituciji ena steklenica vsebuje 1,12 g sildenafila v obliki sildenafilijevega citrata.
In pups of rats which were pre- and postnatally treated with 60 mg/kg sildenafil, a decreased litter size, a lower pup weight on day 1 and a decreased 4-day survival were seen at exposures which were approximately fifty times the expected human intravenous exposure at 10 mg three times a day. 
Pri izpostavljenosti, ki je približno petdesetkrat presegala pričakovano izpostavljenost ob intravenskemu odmerku 10 mg trikrat na dan pri človeku, so pri mladičih podgan, tretiranih pred skotitvijo in po njej s 60 mg sildenafila/kg, ugotovili zmanjšanje velikosti legla, manjšo telesno maso mladičev 1. dan in manjše 4-dnevno preživetje.
Each 20 ml vial contains 12.5 ml of solution (10 mg of sildenafil, as citrate). 
Ena 20 ml viala vsebuje 12,5 ml raztopine (10 mg sildenafila v obliki sildenafilijevega citrata).
In the pivotal placebo-controlled study of Revatio in pulmonary arterial hypertension, a total of 207 patients were randomized to and treated with 20 mg, 40 mg or 80 mg TID doses of oral Revatio and 70 patients were randomized to placebo. 
V ključni, s placebom nadzorovani študiji zdravila Revatio za zdravljenje pljučne arterijske hipertenzije, je skupno 207 bolnikov bilo randomiziranih in zdravljenih s peroralnim zdravilom Revatio v odmerkih 20 mg, 40 mg ali 80 mg trikrat na dan, 70 bolnikov pa je bilo randomiziranih na placebo.
For paediatric patients aged 1 year to 17 years old, the recommended dose in patients ≤ 20 kg is 10 mg (1 ml of reconstituted suspension) three times a day and for patients > 20 kg is 20 mg (2 ml of reconstituted suspension) three times a day. 
Priporočeni odmerek za pediatrične bolnike med 1. in 17. letom starosti in telesno maso ≤ 20 kg je 10 mg (1 ml rekonstituirane suspenzije) trikrat na dan, za bolnike s telesno maso > 20 kg pa 20 mg
In three specific drug-drug interaction studies, the alpha-blocker doxazosin (4 mg and 8 mg) and oral sildenafil (25 mg, 50 mg, or 100 mg) were administered simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy. 
V treh specifičnih študijah interakcij med zdravili so bolnikom z benigno hiperplazijo prostate (BPH), stabiliziranim na zdravljenju z doksazosinom, dali antagonist receptorjev alfa doksazosin (4 mg ali 8 mg) sočasno s peroralnim sildenafilom (25 mg, 50 mg oz. 100 mg).
For paediatric patients aged 1 year to 17 years old, the recommended dose in patients ≤ 20 kg is 10 mg three times a day and for patients > 20 kg is 20 mg three times a day. 
Priporočeni odmerek za pediatrične bolnike med 1. in 17. letom starosti in telesno maso ≤ 20 kg je 10 mg trikrat na dan, za bolnike s telesno maso > 20 kg pa 20 mg trikrat na dan.
Effects of other medicinal products on oral sildenafil 
Učinki drugih zdravil na peroralni sildenafil
Do not use this medicine after the expiry date which is stated on the carton after EXP. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli poleg oznake »Uporabno do:«.
In three specific drug-drug interaction studies, the alpha-blocker doxazosin (4 mg and 8 mg) and sildenafil (25 mg, 50 mg, or 100 mg) were administered simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy. 
V treh specifičnih študijah interakcij med zdravili so bolnikom z benigno hiperplazijo prostate (BPH), stabiliziranim na zdravljenju z doksazosinom, dali antagonist receptorjev alfa doksazosin (4 mg ali 8 mg) sočasno s sildenafilom (25 mg, 50 mg oz. 100 mg).
Each film-coated tablet contains 20 mg of sildenafil (as citrate). 
Ena filmsko obložena tableta vsebuje 20 mg sildenafila v obliki sildenafilijevega citrata.
After chronic oral dosing of 80 mg three times a day to patients with pulmonary arterial hypertension lesser effects in blood pressure reduction were observed (a reduction in both systolic and diastolic pressure of 2 mmHg). 
Po kroničnem peroralnem odmerjanju 80 mg trikrat na dan pri bolnikih s pljučno arterijsko hipertenzijo so opažali manjše učinke na znižanje krvnega tlaka (znižanje sistoličnega in diastoličnega tlaka za 2 mmHg).
A total of 106 out of 234 (45 %) subjects were evaluable for CPET, which comprised those children ≥ 7 years old and developmentally able to perform the test. Children < 7 years (sildenafil combined dose = 47; placebo = 16) were evaluable only for the secondary endpoints. 
CPET je bilo mogoče ovrednotiti pri skupno 106 izmed 234 (45 %) preiskovancev, v tem številu pa so bili zajeti otroci, stari  7 let, ki so bili glede na stopnjo razvoja sposobni opraviti preskus.
MINIMUM PARTICULARS TO APPEAR ON BLISTERS 
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU
Revatio is used to treat adults and children and adolescents from 1 to 17 years old with high blood pressure in the blood vessels in the lungs (pulmonary arterial hypertension). 
Zdravilo Revatio uporabljamo za zdravljenje visokega krvnega tlaka v pljučnih žilah (pljučne arterijske hipertenzije) pri odraslih ter pri otrocih in mladostnikih, starih med 1 in 17 let.
Glucose Water for injections 
6.1 Seznam pomožnih snovi glukoza voda za injekcije
After reconstitution, each ml of the oral suspension contains 10 mg of sildenafil (as citrate) One bottle of reconstituted oral suspension (112 ml) contains 1.12 g of sildenafil (as citrate) 
Ena steklenica rekonstituirane peroralne suspenzije (112 ml) vsebuje 1,12 g sildenafila v obliki sildenafilijevega citrata.
OUTER PACKAGING/CARTON 
ZUNANJA OVOJNINA/ŠKATLA
Each ml of solution contains 0.8 mg of sildenafil (as citrate). 
1 ml raztopine vsebuje 0,8 mg sildenafila v obliki sildenafilijevega citrata.
CYP3A4 inducers seemed to have a substantial impact on the pharmacokinetics of sildenafil in pulmonary arterial hypertension patients, which was confirmed in the in-vivo interaction study with CYP3A4 inducer bosentan. 
Kaže, da induktorji CYP3A4 pri bolnikih s pljučno arterijsko hipertenzijo močno vplivajo na farmakokinetiko sildenafila.
Placebo-corrected treatment effects with mPAP were -2.7 mmHg (p = 0.04), -3.0 mm Hg (p = 0.01) and -5.1 mm Hg (p < 0.0001) for sildenafil 20 mg, 40 mg and 80 mg TID respectively. 
Za placebo korigiran učinek zdravljenja na povprečni pljučni arterijski tlak je bil za 20 mg sildenafila trikrat na dan -2,7 mmHg (p = 0,04), za 40 mg trikrat na dan -3,0 mmHg (p = 0,01) in za 80 mg trikrat na dan -5,1 mmHg (p < 0,0001).
A downward dose adjustment to 10 mg twice daily should be considered after a careful benefit-risk assessment only if therapy is not well-tolerated. 
Le če bolnik zdravljenja ne prenaša dobro, je treba po natančni oceni koristi in tveganj razmisliti o zmanjšanju odmerka na 10 mg dvakrat na dan.
In a placebo-controlled study of Revatio as an adjunct to intravenous epoprostenol in pulmonary arterial hypertension, a total of 134 patients were treated with oral Revatio (in a fixed titration starting from 20 mg, to 40 mg and then 80 mg, three times a day as tolerated) and epoprostenol, and 131 patients were treated with placebo and epoprostenol. 
V študiji, nadzorovani s placebom, v kateri so preučevali zdravilo Revatio kot dodatek intravenskemu epoprostenolu pri pljučni arterijski hipertenziji, je skupno 134 bolnikov dobivalo peroralno zdravilo Revatio (v fiksni titraciji najprej 20 mg, nato 40 mg in 80 mg trikrat na dan, kot so ga prenašali) in epoprostenol, 131 bolnikov pa placebo in epoprostenol.
In a placebo-controlled study of Revatio as an adjunct to intravenous epoprostenol in pulmonary arterial hypertension, a total of 134 patients were treated with Revatio (in a fixed titration starting from 20 mg, to 40 mg and then 80 mg, three times a day as tolerated) and epoprostenol, and 131 patients were treated with placebo and epoprostenol. 
V študiji, nadzorovani s placebom, v kateri so preučevali zdravilo Revatio kot dodatek intravenskemu epoprostenolu pri pljučni arterijski hipertenziji, je skupno 134 bolnikov dobivalo zdravilo Revatio (v fiksni titraciji najprej 20 mg, nato 40 mg in 80 mg trikrat na dan, kot so ga prenašali) in epoprostenol, 131 bolnikov pa placebo in epoprostenol.
CYP3A4 inducers seemed to have a substantial impact on the oral pharmacokinetics of sildenafil in pulmonary arterial hypertension patients, which was confirmed in the in-vivo interaction study with CYP3A4 inducer bosentan. 
Kaže, da induktorji CYP3A4 pri bolnikih s pljučno arterijsko hipertenzijo močno vplivajo na peroralno farmakokinetiko sildenafila.